BACM
ALXN

Blue Arrow Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Blue Arrow Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-10,754
Closed -$1.86M – 189
2015
Q1 		$1.86M Buy
+10,754
New +$1.95M 0.18% 109
2014
Q3 		– Sell
-19,500
Closed -$3.05M – 224
2014
Q2 		$3.05M Buy
+19,500
New +$3.08M 0.41% 66

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Blue Arrow Capital Management's ALXN Position: Q2 2015 in Review

Blue Arrow Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2015, closing a stake of 10,754 shares — an estimated $1.86M sold.

Blue Arrow Capital Management first reported a position in ALXN in Q2 2014 and held it in 2 quarters. The position peaked at $3.05M in Q2 2014. 548 funds tracked by Wall St. Rank hold ALXN as of Q2 2015.

  • Blue Arrow Capital Management reported no remaining Alexion Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Blue Arrow Capital Management sold 10,754 Alexion Pharmaceuticals shares in Q2 2015, an estimated $1.86M.
  • Blue Arrow Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2014 and held it in 2 quarters.
  • Blue Arrow Capital Management's Alexion Pharmaceuticals position peaked at $3.05M in Q2 2014.
  • 548 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2015.

Based on Blue Arrow Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.